Table of Contents

company-logo

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

Intensity Therapeutics Dividend Announcement

• Intensity Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Intensity Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Intensity Therapeutics Dividend History

Intensity Therapeutics Dividend Yield

Intensity Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Intensity Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Intensity Therapeutics Financial Ratios

P/E ratio-2.43
PEG ratio-0.02
P/B ratio14.21
ROE-209.73%
Payout ratio-8.14%
Current ratio1.63
Quick ratio1.63
Cash Ratio1.20

Intensity Therapeutics Dividend FAQ

Does Intensity Therapeutics stock pay dividends?
Intensity Therapeutics does not currently pay dividends to its shareholders.
Has Intensity Therapeutics ever paid a dividend?
No, Intensity Therapeutics has no a history of paying dividends to its shareholders. Intensity Therapeutics is not known for its dividend payments.
Why doesn't Intensity Therapeutics pay dividends?
There are several potential reasons why Intensity Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Intensity Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Intensity Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Intensity Therapeutics a dividend aristocrat?
Intensity Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Intensity Therapeutics a dividend king?
Intensity Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Intensity Therapeutics a dividend stock?
No, Intensity Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Intensity Therapeutics stocks?
To buy Intensity Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Intensity Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.